Learning Objectives:
- Provide a disease overview of hATTR amyloidosis
- Discuss a hypothetical patient case, including symptom presentation and management goals
- Review the clinical efficacy and safety of AMVUTTRA® (vutrisiran) as a treatment option for the polyneuropathy of hATTR amyloidosis in adults
- Provide an overview of Alnylam AssistTM, a patient support program for adults who have been prescribed AMVUTTRA for the polyneuropathy of hATTR amyloidosis
Speakers:
- Amanda Peltier, MD, MS, Vanderbilt University Medical Center
- Brett Sperry, MD, Saint Luke's Mid America Heart Institute
AMVUTTRA and its associated logo are trademarks of Alnylam Pharmaceuticals, Inc.
© 2023 Alnylam Pharmaceuticals, Inc. All rights reserved. AMV-USA-00533